Phase 3 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a type of aggressive lymphoma called DLBCL that tests positive for a protein called CD20, who have either never been treated for lymphoma before, or whose lymphoma has come back or stopped responding to treatment and for whom the trial doctor determines no other standard treatment is suitable
- People who have at least one measurable area of disease that can be detected on scans (either in a lymph node or elsewhere in the body)
- People whose general health and ability to carry out daily activities meets a certain minimum level (confirm with trial site)
- People with a life expectancy of at least 12 months
- People with a certain disease severity score (called the International Prognostic Index) that falls within ranges specified by the trial, depending on which part of the trial they are joining (confirm with trial site)
- People whose blood counts and organ function (such as liver and kidneys) meet the levels required by the trial
Who may not be able to join:
- People whose lymphoma has started in, or has spread to, the brain or spinal cord, or who have certain other neurological conditions
- People who currently have another active cancer, or a serious active disease or medical condition as determined by the trial team
- People with severe nerve damage (called peripheral neuropathy at Grade 3 or higher)
- People who have already received systemic (whole-body) treatment for lymphoma, unless their DLBCL has come back or stopped responding to treatment, or their lymphoma developed from a slower-growing lymphoma that was previously treated
- People who have received any other treatment or experimental therapy within 28 days (or within 5 half-lives of that treatment, whichever is the shorter period) before the trial treatment begins
- People who have had recent major surgery, an organ transplant, or standard radiotherapy (confirm with trial site for specific timeframes)
- People who have a known allergy or sensitivity to any of the medications used in this trial
- People with active infections of any kind (including bacterial, viral, or fungal), active COVID-19, or poorly controlled HIV, Hepatitis B, Hepatitis C, or CMV infections
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence of Dose Limiting Toxicities (DLTs); Incidence of Treatment Emergent Adverse Events (TEAEs); Severity of TEAEs; Progression Free Survival (PFS), assessed by Independent Central Review (ICR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.